Remgro Limited

Remgro reported headline earnings up 42.3% to ZAR 11.1 billion and headline earnings per share up 42.2% to ZAR 20.03. Excluding once-off items of over ZAR 1 billion, headline earnings rose 29.3% to ZAR 10.1 billion. Adjusted free cash flow at the center increased 28.6% to ZAR 4.95 billion, or ZAR 8.91 per share, while free cash flow at the center rose 105.6% to ZAR 8.3 billion. INAV per share increased 4.6% to ZAR 305.80, and total growth including distributions was 8.9%. Cash at the center ended at ZAR 20.4 billion, rising to ZAR 22.5 billion after the Mediclinic equalization dividend. The board declared a final ordinary dividend of ZAR 4.22 per share, bringing full-year ordinary dividends to ZAR 5.95 per share, up 73% year on year, and a special dividend of ZAR 5.50 per share; total cash dividends payable are ZAR 9.72 per share. Mediclinic reported adjusted revenue up 11% to $5.4 billion and adjusted EBITDA up 14% to $842 million. Heineken Beverages reported revenue broadly flat at ZAR 55.3 billion and headline earnings of ZAR 589 million versus a ZAR 268 million loss last year. RCL Foods said EBITDA fell 8.6% and headline earnings fell 27.1%. CIVH revenue rose 14% to ZAR 7.6 billion and operating earnings rose 36%, with headline earnings swinging to a ZAR 560 million profit. Management did not provide formal forward group guidance beyond retaining dividend cover at 1.5x adjusted free cash flow for the foreseeable future and saying they will remain disciplined on new investments.

Jannie Durand framed the year as the second straight year that portfolio actions and focused ownership translated into stronger earnings, cash flow, and returns. She emphasized that the portfolio transformation is now largely complete, with fewer listed entry points and more focus on businesses where Remgro can influence performance directly. Her tone was upbeat but measured, noting that the work is ongoing and that the company does not expect results to move in a straight line.

Neville Williams highlighted that the headline earnings uplift was supported by stronger performance at Rainbow, Mediclinic, CIVH, OUTsurance, and Heineken Beverages, partly offset by weaker RCL Foods. He pointed to one-offs of more than ZAR 1 billion, including a Mediclinic Switzerland tax benefit and tariff provision release, plus a Transnet pipeline cost refund at TotalEnergies, but said the underlying growth was still strong. He also stressed balance-sheet strength: cash at the center rose from roughly ZAR 8.3 billion/ZAR 8.4 billion to over ZAR 20 billion, the company has zero gearing at the center, and adjusted free cash flow supported a 73% increase in the ordinary dividend plus a special dividend of ZAR 5.50 per share. He said the dividend cover target remains 1.5x adjusted free cash flow.

The call was mostly a prepared-results presentation, so there was little direct analyst Q&A in the transcript. The most notable management discussions centered on questions investors would likely have about capital allocation, including whether more buybacks could happen; management said repurchases remain on the table but will be weighed against other opportunities. Another recurring issue was the sustainability of recent gains: management said they remain disciplined on new investments, that the portfolio shift is largely complete, and that RCL, Mediclinic, and Heineken still face specific operational or market risks.